Radiation therapy for extranodal lymphomas. ([2017])

• Record Type: Book
• Further Information: Note: Keisuke Sasai, Masahiko Oguchi, editors.
• Editors: Sasai, Keisuke; Oguchi, Masahiko
• Contents: Preface; Contents; 1: Primary Central Nervous System Lymphomas; 1.1 Introduction; 1.2 Pathology; 1.3 Pretreatment Evaluation; 1.4 Treatment Strategy; 1.5 Chemotherapy; 1.6 Radiation Therapy (Indications); 1.6.1 Consolidation RT in Patients with CR After Chemotherapy; 1.6.2 RT for Refractory or Recurrent PCNSL After Chemotherapy Alone; 1.6.3 RT for Progressive Disease During Initial Chemotherapy; 1.6.4 Re-irradiation for Recurrence After Whole-Brain Radiotherapy; 1.6.5 Palliative RT; 1.6.6 RT in Elderly Patients; 1.6.7 Radiotherapy for Intraocular Involvement by PCNSL. 1.6.8 RT for Primary Intraocular Lymphoma1.7 Radiation Therapy (Treatment Procedures); 1.7.1 RT Planning; 1.7.2 Whole-Brain Radiotherapy (Fig. 1.2); 1.7.2.1 Target Volumes; 1.7.2.2 Radiation Field; 1.7.2.3 Beam Energy; 1.7.2.4 Dose and Fractionation; 1.7.3 Partial Brain RT (Fig. 1.3); 1.7.3.1 Target Volumes; 1.7.3.2 RT Technique; 1.7.3.3 Dose; 1.8 Outcomes; 1.8.1 Survival; 1.8.2 Prognostic Factors; 1.9 Toxicity; 1.9.1 Acute Toxicity; 1.9.2 Late Toxicity; References; 2: Ocular Adnexal Lymphoma; 2.1 Introduction; 2.2 Pathology, Immunophenotype, and Cytogenetic Abnormalities. 2.2.1 MALT Lymphoma2.3 Clinical Features; 2.3.1 MALT Lymphoma; 2.3.2 DLBCL; 2.4 Pretreatment Evaluation and Staging; 2.5 Prognostic Factors; 2.6 Treatment Strategy; 2.6.1 MALT Lymphoma; 2.6.2 Diffuse Large B-Cell Lymphoma; 2.7 Radiation Therapy; 2.7.1 Clinical Target Volume; 2.7.1.1 MALT Lymphoma and Other Indolent Lymphomas; 2.7.1.2 DLBCL and Other Aggressive Lymphomas; 2.7.2 Dose; 2.7.2.1 MALT Lymphoma and Other Indolent Lymphomas; 2.7.2.2 DLBCL; 2.7.3 Radiation Therapy Techniques; 2.8 Outcomes; 2.8.1 MALT Lymphoma; 2.8.1.1 Response. 2.8.1.2 Survival and Disease Progression2.8.2 Diffuse Large B-Cell Lymphoma; 2.9 Toxicity; 2.10 Summary; References; 3: Extranodal NK/T Cell Lymphoma, Nasal Type; 3.1 Introduction; 3.2 Pathology; 3.3 Pretreatment Evaluation and Prognostic factors; 3.4 Treatment Strategy; 3.5 Chemotherapy; 3.6 Radiation Therapy (Indications); 3.7 Radiation Therapy (Treatment Procedures); 3.7.1 RT Planning; 3.7.2 Extended Involved Site Radiation Therapy and Target volumes; 3.7.3 Radiation Delivery; 3.7.4 Dose and Fractionation; 3.8 Outcomes; 3.8.1 Survival; 3.8.2 Failure Patterns. 3.9 Toxicity3.9.1 Acute Toxicity; 3.9.2 Late Toxicity; References; 4: Thyroid Lymphoma; 4.1 Introduction; 4.2 Pathology; 4.3 Lymphoma Subtype for Radiation Therapy; 4.4 Pretreatment Evaluation and Staging; 4.5 Prognostic Factors; 4.6 Treatment Strategy; 4.6.1 DLBCL; 4.6.2 MALT; 4.7 Radiation Therapy; 4.7.1 Planning CT; 4.7.2 Gross Tumor Volume (GTV); 4.7.3 Clinical Target Volume (CTV) and Planning Target Volume (PTV); 4.7.4 Dose; 4.7.5 Radiation Therapy Techniques; 4.8 Outcomes; 4.9 Toxicity; References; 5: Pyothorax-Associated Lymphoma; 5.1 Etiology and Pathology.
• Publisher Details: Tokyo, Japan : Springer Nature
• Publication Date: 2017
• Copyright Date: 2017
• Extent: 1 online resource
• Subjects: 616.99/446; Lymphomas; Lymphomas -- Treatment; Radiotherapy; HEALTH & FITNESS -- Diseases -- General; MEDICAL -- Clinical Medicine; MEDICAL -- Diseases; MEDICAL -- Evidence-Based Medicine; MEDICAL -- Internal Medicine; Lymphomas; Lymphomas -- Treatment; Radiotherapy; Lymphoma -- radiotherapy; Electronic books
• Languages: English
• ISBNs: 9784431564355; 4431564357
• Related ISBNs: 9784431564331
• Notes: Note: Includes bibliographical references.; Note: Vendor-supplied metadata.
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.